CRSP FY2028 EPS Decreased by Brookline Capital Acquisition

CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities researchers at Brookline Capital Acquisition cut their FY2028 earnings estimates for shares of CRISPR Therapeutics in a research note issued to investors on Wednesday, March 11th. Brookline Capital Acquisition analyst L. Cann now anticipates that the company will post earnings of $7.44 per share for the year, down from their previous estimate of $7.47. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share. Brookline Capital Acquisition also issued estimates for CRISPR Therapeutics’ FY2029 earnings at $38.50 EPS and FY2030 earnings at $139.09 EPS.

A number of other equities research analysts also recently issued reports on the stock. Evercore reissued an “outperform” rating and set a $74.00 price target on shares of CRISPR Therapeutics in a research note on Friday, February 13th. Citigroup reaffirmed a “buy” rating on shares of CRISPR Therapeutics in a research note on Monday, February 16th. Chardan Capital lifted their price objective on CRISPR Therapeutics from $74.00 to $76.00 and gave the stock a “buy” rating in a report on Saturday, February 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Wednesday, January 21st. Finally, Bank of America lowered their target price on CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating on the stock in a report on Thursday, January 22nd. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, CRISPR Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $64.24.

CRISPR Therapeutics Trading Down 2.1%

Shares of CRSP opened at $48.87 on Thursday. CRISPR Therapeutics has a twelve month low of $30.04 and a twelve month high of $78.48. The firm has a market capitalization of $4.69 billion, a P/E ratio of -7.50 and a beta of 1.72. The firm’s 50-day moving average is $54.20 and its two-hundred day moving average is $57.28.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Thursday, February 12th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The company had revenue of $0.86 million during the quarter, compared to analysts’ expectations of $4.72 million. During the same quarter in the prior year, the business earned ($1.01) EPS. The business’s revenue for the quarter was down 97.8% compared to the same quarter last year.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada boosted its stake in shares of CRISPR Therapeutics by 28.2% during the first quarter. Royal Bank of Canada now owns 142,696 shares of the company’s stock valued at $4,856,000 after acquiring an additional 31,392 shares during the last quarter. AQR Capital Management LLC purchased a new position in CRISPR Therapeutics in the 1st quarter valued at about $861,000. Woodline Partners LP lifted its holdings in CRISPR Therapeutics by 34.3% in the 1st quarter. Woodline Partners LP now owns 136,483 shares of the company’s stock valued at $4,645,000 after purchasing an additional 34,883 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of CRISPR Therapeutics by 288.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 301,959 shares of the company’s stock worth $14,687,000 after purchasing an additional 224,257 shares during the last quarter. Finally, Atlantic Union Bankshares Corp acquired a new stake in shares of CRISPR Therapeutics during the 2nd quarter worth about $33,000. 69.20% of the stock is owned by institutional investors and hedge funds.

Insider Activity at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 9,798 shares of the firm’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $52.80, for a total transaction of $517,334.40. Following the completion of the transaction, the chief executive officer directly owned 235,558 shares of the company’s stock, valued at $12,437,462.40. This trade represents a 3.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel James R. Kasinger sold 2,800 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $52.80, for a total value of $147,840.00. Following the transaction, the general counsel owned 87,815 shares of the company’s stock, valued at $4,636,632. This represents a 3.09% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 111,677 shares of company stock worth $6,308,848 over the last quarter. Company insiders own 4.30% of the company’s stock.

More CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Upsized convertible notes provide cash runway — CRSP priced $550M of convertible senior notes due 2031 (option for +$50M) with estimated net proceeds ≈ $536.3M to fund general corporate purposes; upsizing suggests strong investor demand and reduces near‑term liquidity pressure. GlobeNewswire: Convertible Notes
• Positive Sentiment: Institutional buying interest reported (e.g., ARK additions noted in coverage) can support longer-term demand even as volatility spikes from the financing headlines. Blockonomi: ARK Buys
• Neutral Sentiment: Small analyst estimate cuts from Brookline Capital Acquisition for FY2028–FY2030 (minor downward tweaks to long‑range EPS forecasts). These moves are marginal vs. consensus and more informational than catalytic alone.
• Neutral Sentiment: Short-interest data in some feeds showed zero or NaN values for March filings (likely a reporting/data glitch) — not a reliable signal of increased short pressure this session.
• Negative Sentiment: Convertible terms carry dilution risk — conversion price ≈ $76.56 (≈45% premium to the March 10 close), and conversion or eventual share issuance would dilute existing holders if notes convert or are hedged into shares; issuance also increases leverage and has tax-adjusted coupon implications. QuiverQuant: Notes Details
• Negative Sentiment: Insider sales (CEO Samarth Kulkarni sold 9,798 shares at ~$52.80; General Counsel James Kasinger sold 2,800 shares at ~$52.80) were disclosed March 11–12. Repeated insider selling this past year (many sales vs. no purchases) can weigh on sentiment even if each filing says routine/for diversification. CEO SEC Filing GC SEC Filing
• Negative Sentiment: Underlying fundamentals remain mixed: recent quarterly results showed a revenue ramp from CASGEVY but prior EPS misses and heavy R&D spend leave the company loss-making — investors can react negatively to financing when combined with prior earnings volatility.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.